Roche Aktie

311,70 EUR +0,20 EUR +0,06 %

18:29:28

L&S

295,30 CHF +0,60 CHF +0,20 %

17:35:50

SWX

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.248,89 Mrd. EUR

KGV24,60Div. Rendite3,80%

WKN855167

ISINCH0012032048

SymbolRHHVF

Roche Aktien News

Sortieren:Datum Meistgelesen

12.02.25GlobeNewswireFDA approves Roche’s Evrysdi tablet as first and only tablet for Spinal Muscular Atrophy (SMA)

12.02.25Roche Holding AGFDA approves Roche’s Evrysdi tablet as first and only tablet for Spinal Muscular Atrophy (SMA)

07.02.25GlobeNewswireNew England Journal of Medicine publishes new data for Roche’s Gazyva/Gazyvaro which shows superiority over standard therapy in people with active lupus nephritis

WerbungRoche-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

07.02.25Roche Holding AGNew England Journal of Medicine publishes new data for Roche’s Gazyva/Gazyvaro which shows superiority over standard therapy in people with active lupus nephritis

04.02.25GlobeNewswireFDA approves Roche’s Susvimo as the first and only continuous delivery treatment for the leading cause of diabetes-related blindness

04.02.25Roche Holding AGFDA approves Roche’s Susvimo as the first and only continuous delivery treatment for the leading cause of diabetes-related blindness

31.01.25GlobeNewswireRoche receives FDA approval for the first companion diagnostic to identify patients with HER2-ultralow metastatic breast cancer eligible for ENHERTU

31.01.25Roche Holding AGRoche receives FDA approval for the first companion diagnostic to identify patients with HER2-ultralow metastatic breast cancer eligible for ENHERTU

30.01.25Roche Holding AG[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2024 results with 7% sales growth; fourth quarter marks third straight quarter of 9% growth

30.01.25GlobeNewswire[Ad-hoc-Mitteilung gemäss Art. 53 KR] Roche erzielt starkes Jahresergebnis für 2024 mit Verkaufswachstum von 7%; drittes Quartal in Folge mit 9% Wachstum

30.01.25GlobeNewswire[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2024 results with 7% sales growth; fourth quarter marks third straight quarter of 9% growth

29.01.25GlobeNewswireChange to the Roche Enlarged Corporate Executive Committee

29.01.25Roche Holding AGChange to the Roche Enlarged Corporate Executive Committee

28.01.25Roche Holding AGRoche’s Itovebi demonstrated statistically significant and clinically meaningful overall survival benefit in a certain type of HR-positive advanced breast cancer

28.01.25GlobeNewswireRoche’s Itovebi demonstrated statistically significant and clinically meaningful overall survival benefit in a certain type of HR-positive advanced breast cancer

27.01.25GlobeNewswireRoche announces new results from EMBARK demonstrating significant sustained benefits of Elevidys in ambulatory individuals with Duchenne muscular dystrophy (DMD)

27.01.25Roche Holding AGRoche announces new results from EMBARK demonstrating significant sustained benefits of Elevidys in ambulatory individuals with Duchenne muscular dystrophy (DMD)

22.01.25Roche Holding AGRoche receives FDA clearance with CLIA waiver for cobas® liat molecular tests to diagnose sexually transmitted infections at the point of care

22.01.25GlobeNewswireRoche receives FDA clearance with CLIA waiver for cobas® liat molecular tests to diagnose sexually transmitted infections at the point of care

13.01.25PR NewswireRoche receives FDA clearance for new, highly-sensitive test to aid clinicians in diagnosing B-cell lymphoma

09.01.25PR NewswireRoche's momentum in digital pathology continues with FDA clearance on its high-volume slide scanner

08.01.25GlobeNewswireRoche purchases shares in tender offer for Poseida Therapeutics, Inc.

08.01.25Roche Holding AGRoche purchases shares in tender offer for Poseida Therapeutics, Inc.

19.12.24Roche Holding AGRoche’s Phase IIb study of prasinezumab missed primary endpoint, but suggests possible benefit in early-stage Parkinson’s disease

19.12.24GlobeNewswireRoche’s Phase IIb study of prasinezumab missed primary endpoint, but suggests possible benefit in early-stage Parkinson’s disease

18.12.24GlobeNewswireRoche transforms mass spectrometry diagnostics with launch of cobas® Mass Spec solution

18.12.24Roche Holding AGRoche transforms mass spectrometry diagnostics with launch of cobas® Mass Spec solution

13.12.24GlobeNewswireRoche’s Vabysmo prefilled syringe (PFS) approved in the EU for three retinal conditions that can cause blindness

13.12.24Roche Holding AGRoche receives CE Mark for new and updated molecular cobas 6800/8800 systems, enhancing laboratory efficiency and testing capabilities

13.12.24GlobeNewswireRoche receives CE Mark for new and updated molecular cobas 6800/8800 systems, enhancing laboratory efficiency and testing capabilities

10.12.24Roche Holding AGNew and updated data for Roche's fixed-duration Columvi and Lunsumio at ASH 2024 reinforce their potential to improve outcomes for people with lymphoma

10.12.24GlobeNewswireNew and updated data for Roche's fixed-duration Columvi and Lunsumio at ASH 2024 reinforce their potential to improve outcomes for people with lymphoma

09.12.24GlobeNewswireRoche commences tender offer for all shares of Poseida Therapeutics, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right for up to $4.00 per share in cash

09.12.24Roche Holding AGRoche commences tender offer for all shares of Poseida Therapeutics, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right for up to $4.00 per share in cash

08.12.24GlobeNewswireFive-year results confirm Roche’s Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma

08.12.24Roche Holding AGFive-year results confirm Roche’s Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma

05.12.24Roche Holding AGFDA accepts supplemental Biologics License Application for Roche’s Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma

05.12.24GlobeNewswireFDA accepts supplemental Biologics License Application for Roche’s Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma

26.11.24GlobeNewswireRoche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies

26.11.24Roche Holding AGRoche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies

Roche News

Roche News: auf dieser Seite finden Sie alle Roche News und Nachrichten zur Roche Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Roche News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Roche News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.